What do systematic reviews say?

Intervention not reported

• Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears) 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 302 participants
  High

Intervention not reported

• Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears) 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 188 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in participant‐reported success Last (low certainty).

• Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears) 2022 · Cochrane Headline outcomes only
  RR 1.11 [0.66, 1.86]
  3 studies · 189 participants
  Low

Intervention not reported

The intervention showed no clear difference in serious adverse eventsLast (low certainty).

• Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears) 2022 · Cochrane Headline outcomes only
  RR 1.35 [0.64, 2.83]
  8 studies · 1206 participants
  Low

Intervention not reported

The intervention showed no clear difference in total adverse events Last (low certainty).

• Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears) 2022 · Cochrane Headline outcomes only
  RR 1.15 [0.78, 1.7]
  9 studies · 1326 participants
  Low

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Small‐volume residual disease (SVRD) < 1 cm probably leads to higher overall survival: Median length of compared with NMRD (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.03 [1.8, 2.29]
  17 studies · 9404 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

The review found no eligible studies for this question.

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.6 [1.21, 2.11]
  6 studies · 1572 participants
  Very low

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.76 [1.23, 2.52]
  4 studies · 1145 participants
  Very low

Residual disease (RD) > 0 cm vs NMRD

It is very uncertain whether residual disease (RD) > 0 cm changes overall survival: Median length of compared with NMRD (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.11 [1.35, 3.29]
  4 studies · 906 participants
  Very low

Residual disease (RD) > 0 cm vs NMRD

It is very uncertain whether residual disease (RD) > 0 cm changes progression‐free survival: Median length of compared with NMRD (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.36 [1.05, 1.76]
  1 study · 471 participants
  Very low

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Small‐volume residual disease (SVRD) < 1 cm probably leads to higher progression‐free survival: Median length of compared with NMRD (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.88 [1.63, 2.16]
  10 studies · 6596 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.5 [2.13, 2.94]
  14 studies · 7988 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.1 [1.84, 2.4]
  6 studies · 2629 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.22 [1.13, 1.32]
  5 studies · 6000 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.3 [1.08, 1.56]
  2 studies · 3402 participants
  Moderate

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

It is very uncertain whether small‐volume residual disease (SVRD) (< 1 cm) changes overall survival: Median length of compared with NMRD (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.09 [1.2, 3.6]
  1 study · 310 participants
  Very low

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 322 participants
  Very low

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with no macroscopic residual disease (NMRD) (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.23 [1.49, 3.34]
  1 study · 343 participants
  Very low

Postoperative use of LNG‐IUD vs postoperative GnRH‐a

• Levonorgestrel‐releasing intrauterine device (LNG‐IUD) for symptomatic endometriosis following surgery 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Very low